Yousif Capital Management LLC grew its position in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) by 6.9% during the 4th quarter, Holdings Channel.com reports. The firm owned 60,538 shares of the company’s stock after purchasing an additional 3,900 shares during the quarter. Yousif Capital Management LLC’s holdings in Novo Nordisk A/S were worth $6,263,000 at the end of the most recent quarter.
Other hedge funds also recently modified their holdings of the company. Westside Investment Management Inc. boosted its stake in shares of Novo Nordisk A/S by 83.3% during the 3rd quarter. Westside Investment Management Inc. now owns 1,428 shares of the company’s stock worth $130,000 after purchasing an additional 649 shares during the last quarter. Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD acquired a new stake in shares of Novo Nordisk A/S in the third quarter worth approximately $2,408,000. Lazard Asset Management LLC boosted its position in shares of Novo Nordisk A/S by 182.2% in the third quarter. Lazard Asset Management LLC now owns 1,494,214 shares of the company’s stock worth $135,883,000 after acquiring an additional 964,640 shares during the last quarter. CENTRAL TRUST Co boosted its position in shares of Novo Nordisk A/S by 111.6% in the third quarter. CENTRAL TRUST Co now owns 6,004 shares of the company’s stock worth $546,000 after acquiring an additional 3,166 shares during the last quarter. Finally, Ieq Capital LLC boosted its position in shares of Novo Nordisk A/S by 136.6% in the third quarter. Ieq Capital LLC now owns 27,474 shares of the company’s stock worth $2,498,000 after acquiring an additional 15,860 shares during the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.
Novo Nordisk A/S Trading Down 0.3 %
NVO opened at $125.80 on Friday. The firm has a market capitalization of $564.53 billion, a P/E ratio of 46.51, a P/E/G ratio of 2.11 and a beta of 0.41. The firm’s 50 day moving average is $126.80 and its 200-day moving average is $111.74. Novo Nordisk A/S has a 52-week low of $75.56 and a 52-week high of $138.28. The company has a quick ratio of 0.64, a current ratio of 0.82 and a debt-to-equity ratio of 0.19.
Novo Nordisk A/S Increases Dividend
The business also recently declared a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Investors of record on Monday, March 25th were paid a $0.664 dividend. This represents a dividend yield of 0.9%. The ex-dividend date was Friday, March 22nd. This is a positive change from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. Novo Nordisk A/S’s payout ratio is 49.17%.
Wall Street Analyst Weigh In
Several equities research analysts recently issued reports on NVO shares. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research report on Thursday, April 18th. BMO Capital Markets started coverage on shares of Novo Nordisk A/S in a research report on Friday, April 12th. They set an “outperform” rating and a $163.00 price target on the stock. Morgan Stanley started coverage on shares of Novo Nordisk A/S in a research report on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 price target on the stock. Finally, UBS Group started coverage on shares of Novo Nordisk A/S in a research report on Tuesday, January 16th. They set a “neutral” rating on the stock. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Novo Nordisk A/S presently has an average rating of “Moderate Buy” and an average price target of $133.60.
Read Our Latest Stock Analysis on NVO
About Novo Nordisk A/S
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
See Also
- Five stocks we like better than Novo Nordisk A/S
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Microsoft Fires a Trend Following Signal: Targets Move Higher
- What is a Low P/E Ratio and What Does it Tell Investors?
- Semiconductor Shakeout: Finding Potential Amidst Turmoil
- What to Know About Investing in Penny Stocks
- Hasbro’s Management Made All the Right Calls This Quarter
Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO – Free Report).
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.